LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Donated Blood Could Be Transformed Into Universal Type

By LabMedica International staff writers
Posted on 10 May 2015
Print article
Image: Hemagglutination test of red cells used for typing ABO blood groups (Photo courtesy of University College London).
Image: Hemagglutination test of red cells used for typing ABO blood groups (Photo courtesy of University College London).
Blood transfusions are critically important in many medical procedures, but the presence of antigens on erythrocytes means that careful blood-typing must be carried out prior to transfusion to avoid adverse and sometimes fatal reactions following transfusion.

Every day, thousands of people need donated blood, but only blood without A- or B-type antigens, such as type O, can be given to all of those in need, and it's usually in short supply. However an efficient way to transform A and B blood into a neutral type that can be given to any patient has been reported.

Scientists at the University of British Columbia (Vancouver, BC, Canada) working with other Canadian and French investigators studied how to enzymatically remove the terminal N-acetylgalactosamine or galactose of A- or B-antigens, respectively, which would yield universal O-type blood. They started with the family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71 which cleaves the entire terminal trisaccharide antigenic determinants of both A- and B-antigens from some of the linkages on red blood cell surface glycans. Through several rounds of evolution, they developed variants with vastly improved activity toward some of the linkages that are resistant to cleavage by the wild-type enzyme.

The investigators fine-tuned one of those enzymes and improved its ability to remove type-determining sugars by 170-fold, rendering it antigen-neutral and more likely to be accepted by patients regardless of their blood type. The authors concluded that the resulting enzyme effects more complete removal of blood group antigens from cell surfaces, demonstrating the potential for engineering enzymes to generate antigen-null blood from donors of various types. In addition to blood transfusions, the scientists say their advance could potentially allow organ and tissue transplants from donors that would otherwise be mismatched. The study was published on April 14, 2015, in the Journal of the American Chemical Society.

Related Links:

University of British Columbia 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more